SCHEMBL10135116

SCHEMBL10135116

N#Cc1ccc2c(c1)nc(Oc1cccc(Cl)c1)c1ccsc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
CSNK2A1 P68400 6/20 0.41
CSNK2A2 P19784 2/20 0.41
CSNK2B P67870 2/20 0.41
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
EGFR P00533 1/20 0.38
LCK P06239 1/20 0.38
AR P10275 1/20 0.35
CYP2C9 P11712 3/20 0.35
CYP1A2 P05177 2/20 0.35
USP2 O75604 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.35
HIF1A Q16665 1/20 0.35
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2689569 0.88 CSNK2A1 (0.44) CSNK2A1CSNK2A2CSNK2BCYP2C9CYP1A2
SCHEMBL10135110 0.83 CSNK2A1 (0.39) CSNK2A1CSNK2A2CSNK2BCNR1CNR2
SCHEMBL13688077 0.83 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BEGFRLCK
SCHEMBL10135115 0.81 CSNK2A1 (0.42) CSNK2A1CSNK2A2CSNK2BCYP2C9CYP1A2
SCHEMBL10135113 0.80 CSNK2A1 (0.38) CSNK2A1CSNK2A2CSNK2BALDH1A1MAP4K4
SCHEMBL10135114 0.77 RAB9A (0.47) CSNK2A1CSNK2A2CSNK2BCYP2C9CYP1A2
SCHEMBL1451465 0.76 CSNK2A1 (0.45) CSNK2A1CSNK2BMAP4K4
SCHEMBL10135123 0.76 CSNK2A1 (0.44) CSNK2A1CSNK2A2CSNK2BEGFRLCK
SCHEMBL10135098 0.73 CSNK2A1 (0.45) CSNK2A1CSNK2A2CSNK2BCNR1
SCHEMBL10135095 0.72 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BCNR1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CYP19A1 2911/4885CSNK2A1 680/4885CSNK2A2 810/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CYP19A1 2911/4885CSNK2A1 680/4885CSNK2A2 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.